Long-term safety and effectiveness of tumour necrosis factor inhibitors in systemic sclerosis patients with inflammatory arthritis

Clinical and Experimental Rheumatology

Volumn 30, Issue SUPPL.71, 2012, Pages

  Omair, Mohammed A ^a   Phumethum, Veerapong ^b   Johnson, Sindhu R ^a  

^a TORONTO WESTERN HOSPITAL   (Canada)

^b PRAPOKKLAO HOSPITAL   (Thailand)

Author keywords

Arthritis; Malignancy; Scleroderma; Systemic sclerosis; Tumour necrosis factor inhibitors

Indexed keywords

ADALIMUMAB; AZATHIOPRINE; ETANERCEPT; HYDROXYCHLOROQUINE; INFLIXIMAB; METHOTREXATE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PREDNISONE;

ADULT; ARTHRALGIA; ARTHRITIS; ARTICLE; BASAL CELL CARCINOMA; BREAST CANCER; CHRONIC MYELOID LEUKEMIA; CLINICAL ARTICLE; CLINICAL EFFECTIVENESS; CLINICAL EVALUATION; CONGESTIVE HEART FAILURE; CONTROLLED STUDY; DISEASE SEVERITY; DRUG EFFICACY; DRUG FATALITY; DRUG HYPERSENSITIVITY; DRUG SAFETY; FEMALE; FORCED VITAL CAPACITY; HERPES ZOSTER; HUMAN; INFECTION; JOINT SWELLING; LUNG CAPACITY; LUPUS VULGARIS; MALE; NEUROLOGIC DISEASE; OUTCOME ASSESSMENT; PAIN ASSESSMENT; PRIORITY JOURNAL; RETROSPECTIVE STUDY; SYSTEMIC SCLEROSIS; TREATMENT DURATION;

ANTI-INFLAMMATORY AGENTS; ARTHRITIS; BREAST NEOPLASMS; CARCINOMA, BASAL CELL; FEMALE; HUMANS; LEUKEMIA, MYELOGENOUS, CHRONIC, BCR-ABL POSITIVE; MALE; MIDDLE AGED; ONTARIO; RETROSPECTIVE STUDIES; SCLERODERMA, SYSTEMIC; SKIN NEOPLASMS; TIME FACTORS; TREATMENT OUTCOME; TUMOR NECROSIS FACTORS;

EID: 84867368217     PISSN: 0392856X     EISSN: 1593098X     Source Type: Journal    
DOI: None     Document Type: Article

References (39)

1. Misra R, Darton K, Jewkes RF et al.: Arthritis in scleroderma. Br J Rheumatol 1995; 34: 831-7.
2. La Montagna G, Baruffo A, Tirri R, BUONO G, VALENTINI G: Foot involvement in systemic sclerosis: a longitudinal study of 100 patients. Semin Arthritis Rheum 2002; 31: 248-55.
3. Avouac J, Walker U, Tyndall A et al.: Characteristics of joint involvement and relationships with systemic inflammation in systemic sclerosis: results from the EULAR Scleroderma Trial and Research Group (EUSTAR) database. J Rheumatol 2010; 37: 1488-501.
4. Kowal-Bielecka O, Landewé R, Avouac J et al.: EULAR recommendations for the treatment of systemic sclerosis: a report from the EULAR Scleroderma Trials and Research group (EUSTAR). Ann Rheum Dis 2009; 68: 620-8.
5. Furst DE, Keystone EC, Fleischmann R et al.: Updated consensus statement on biological agents for the treatment of rheumatic diseases. Ann Rheum Dis 2009; 69 (Suppl. 1): i2-29.
6. Silva LC, Ortigosa LC, Benard G: Anti-TNF-alpha agents in the treatment of immune-mediated inflammatory diseases: mechanisms of action and pitfalls. Immunotherapy; 2: 817-33.
7. Patkar NM, Teng GG, Curtis JR, SAAG KG: Association of infections and tuberculosis with antitumor necrosis factor alpha therapy. Curr Opin Rheumatol 2008; 20: 320-6.
8. Williams EL, Gadola S, Edwards CJ: Anti-TNF-induced lupus. Rheumatology (Oxford) 2009; 48: 716-20.
9. Magnano MD, Robinson WH, Genovese MC: Demyelination and inhibition of tumor necrosis factor (TNF). Clin Exp Rheumatol 2004; 22 (Suppl. 35): S134-40.
10. Bongartz T, Sutton AJ, Sweeting MJ, Buchan I, Matteson EL, Montori V: Anti-TNF antibody therapy in rheumatoid arthritis and the risk of serious infections and malignancies: systematic review and meta-analysis of rare harmful effects in randomized controlled trials. JAMA 2006; 295: 2275-85.
11. Keystone EC: Does anti-tumor necrosis factor-a therapy affect risk of serious infection and cancer in patients with rheumatoid arthritis?: a review of longterm data. J Rheumatol 2011; 38: 1552-62.
12. Phumethum V, Jamal S, Johnson SR: Biologic therapy for systemic sclerosis: a systematic review. J Rheumatol 2011; 38: 289-96.
13. Lam GK, Hummers LK, Woods A, WIGLEY FM: Efficacy and safety of etanercept in the treatment of scleroderma-associated joint disease. J Rheumatol 2007; 34: 1636-7.
14. Ellman MH, Macdonald PA, Hayes FA: Etanercept as treatment for diffuse scleroderma: A pilot study [abstract]. Arthritis Rheum 2000; 43 (Suppl.): S392.
15. Marie I, Lahaxe L, Levesque H, Heliot P: Pulmonary actinomycosis in a patient with diffuse systemic sclerosis treated with infliximab. QJM 2008; 101: 419-21.
16. Denton CP, Engelhart M, Tvede N et al.: An open-label pilot study of infliximab therapy in diffuse cutaneous systemic sclerosis. Ann Rheum Dis 2009; 68: 1433-9.
17. Bosello S, De Santis M, Tolusso B, Zoli A, Ferraccioli G: Tumor necrosis factor-alpha inhibitor therapy in erosive poly arthritis secondary to systemic sclerosis. Ann Intern Med 2005; 143: 918-20.
18. PRELIMINARY CRITERIA FOR THE CLASSIFICATION OF SYSTEMIC SCLEROSIS (SCLERODERMA): Subcommittee for scleroderma criteria of the American Rheumatism Association Diagnostic and Therapeutic Criteria Committee. Arthritis Rheum 1980; 23: 581-90.
19. Rodnan GP: The nature of joint involvement in progressive systemic sclerosis (diffuse scleroderma). Ann Intern Med 1962; 56: 422-39.
20. Avouac J, Guerini H, Wipff J et al.: Radiological hand involvement in systemic sclerosis. Ann Rheum Dis 2006; 65: 1088-92.
21. Cuomo G, Zappia M, Abignano G, Iudici M, Rotondo A, Valentini G: Ultrasonographic features of the hand and wrist in systemic sclerosis. Rheumatology (Oxford) 2009; 48: 1414-7.
22. Low AH, Lax M, Johnson SR, Lee P: Magnetic resonance imaging of the hand in systemic sclerosis. J Rheumatol 2009; 36: 961-4.
23. Ouimet JM, Pope JE, Gutmanis I, Koval J: Work disability in scleroderma is greater than in rheumatoid arthritis and is predicted by high HAQ scores. Open Rheumatol J 2008; 2: 44-52.
24. Gruschwitz MS, Albrecht M, Vieth G, Haustein UF: In situ expression and serum levels of tumor necrosis factor-alpha receptors in patients with early stages of systemic sclerosis. J Rheumatol 1997; 24: 1936-43.
25. Hebbar M, Gillot JM, Hachulla E et al.: Early expression of E-selectin, tumor necrosis factor alpha, and mast cell infiltration in the salivary glands of patients with systemic sclerosis. Arthritis Rheum 1996; 39: 1161-5.
26. Schmidt K, Martinez-Gamboa L, Meier S et al.: Bronchoalveoloar lavage fluid cytokines and chemokines as markers and predictors for the outcome of interstitial lung disease in systemic sclerosis patients. Arthritis Res Ther 2009; 11: R111.
27. Hasegawa M, Fujimoto M, Kikuchi K, Takehara K: Elevated serum tumor necrosis factor-alpha levels in patients with systemic sclerosis: association with pulmonary fibrosis. J Rheumatol 1997; 24: 663-5.
28. Liu JY, Brass DM, Hoyle GW, Brody AR: TNF-alpha receptor knockout mice are protected from the fibroproliferative effects of inhaled asbestos fibers. Am J Pathol 1998; 153: 1839-47.
29. Ortiz LA, Lasky J, Lungarella G et al.: Upregulation of the p75 but not the p55 TNFalpha receptor mRNA after silica and bleomycin exposure and protection from lung injury in double receptor knockout mice. Am J Respir Cell Mol Biol 1999; 20: 825-33.
30. Ito A, Sato T, Iga T, Mori Y: Tumor necrosis factor bifunctionally regulates matrix metalloproteinases and tissue inhibitor of metalloproteinases (TIMP) production by human fibroblasts. FEBS Lett 1990; 269: 93-5.
31. Johnson SR, Glaman DD, Schentag CT, Lee P: Quality of life and functional status in systemic sclerosis compared to other rheumatic diseases. J Rheumatol 2006; 33: 1117-22.
32. Perez-Alvarez R, Perez-De-Lis M, Diazlagares C et al.: Interstitial lung disease induced or exacerbated by TNF-targeted therapies: analysis of 122 cases. Semin Arthritis Rheum 2011; 41: 256-64.
33. Tyndall AJ, Bannert B, Vonk M et al.: Causes and risk factors for death in systemic sclerosis: a study from the EULAR Scleroderma Trials and Research (EUSTAR) database. Ann Rheum Dis 2010; 69: 1809-15.
34. Marasini B, Conciato L, Belloli L, Massarotti M: Systemic sclerosis and cancer. Int J Immunopathol Pharmacol 2009; 22: 573-8.
35. Kasifoglu T, Korkmaz C, Yasar S, Gulbas Z: Scleroderma and chronic myeloid leukemia: a sheer coincidence, a consequence of long lasting D-penicillamine therapy or a plausible relationship of both diseases? Rheumatol Int 2006; 27: 175-7.
36. Olesen AB, Svaerke C, Farkas DKEA: Systemic sclerosis and the risk of cancer: a nationwide population-based cohort study. Br J Dermatol 2010; 163: 800-6.
37. Kuo CF, See LC, Yu KH et al.: Epidemiology and mortality of systemic sclerosis: a nationwide population study in Taiwan. Scand J Rheumatol 2011; 40: 373-8.
38. Chatterjee S, Dombi GW, Severson RK, Mayes MD: Risk of malignancy in scleroderma: a population-based cohort study. Arthritis Rheum 2005; 52: 2415-24.
39. WEGENER'S GRANULOMATOSIS ETANERCEPT TRIAL (WGET) RESEARCH GROUP: Etanercept plus standard therapy for Wegener's granulomatosis. N Engl J Med 2005; 352: 351-61.